Tag: evaluation

The Precipitated Silica Market Companies Quadrant presents an in-depth analysis of the global precipitated silica market, highlighting top industry players like Evonik Industries AG, Solvay SA, and Tata Chemicals Ltd. With over 40 companies evaluated, the Top 15 emerge as quadrant leaders, driven by innovations, strategic expansions, and a focus on sustainability. The increasing demand across automotive, agriculture, cosmetics, and electronics sectors underscores precipitated silica's versatility. This customizable silicon dioxide improves tire efficiency, supports crop protection, and enhances cosmetic formulations. As industries prioritize sustainability, the role of precipitated silica continues to grow.

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI^® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.¹

Investors can contact the law firm at no cost to learn more about recovering their losses

^{All financial figures are in Canadian dollars unless otherwise noted}

CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the evaluation of arimoclomol for the treatment of Niemann-Pick Disease Type C (NPC). NPC is an ultra-rare, neurological disease caused by genetic mutations that result in lipid accumulation in cells, leading to visceral, neurological, and psychiatric symptoms. Arimoclomol is the only treatment shown to directly target the underlying pathology of NPC by increasing gene expression for improved lipid clearance. Arimoclomol for the treatment of NPC has been designated as an Orphan Medicinal Product by the EMA. Arimoclomol is marketed in the U.S. under the brand name MIPLYFFA®.